A Phase 1, Double Blind (Sponsor Open), Placebo-controlled, Multiple-dose Study To Evaluate The Tolerability, Safety And Pharmacokinetics Of A Modified Release Formulation Of Pf-06650833 Under Fed Condition In Healthy Adult Japanese Subjects
Latest Information Update: 23 Oct 2017
At a glance
- Drugs Zimlovisertib (Primary)
- Indications Lupus-like syndrome
- Focus Adverse reactions
- Sponsors Pfizer
- 21 Oct 2016 New trial record